Our results showed that information based on MGRN1 expression in combination with PMEL, MLANA, and TYRP1 reliably complemented the prognostic information of TNM staging, underlining the potential of this small set of genes as an accurate and sensitive prognostic biomarker for MM. This evidence concerns the gene MLANA and Miyoshi myopathy.